Announcements
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
- Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
- Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
- CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
- Organovo to Participate in the H.C. Wainwright Global Investment Conference
- Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
More ▼
Key statistics
As of last trade, Organovo Holdings Inc (4OR1:BER) traded at 0.93, 11.51% above the 52 week low of 0.834 set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.932 |
---|---|
High | 0.937 |
Low | 0.925 |
Bid | 0.86 |
Offer | 0.989 |
Previous close | 0.95 |
Average volume | 73.18k |
---|---|
Shares outstanding | 10.04m |
Free float | 9.85m |
P/E (TTM) | -- |
Market cap | 10.04m USD |
EPS (TTM) | -2.17 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 16:42 BST.
More ▼